Jacobio Pharmaceuticals Group (JBPHF) Stock Price, News & Analysis

Company Overview

Jacobio Pharmaceuticals Group is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for cancer. The company uses proprietary drug-discovery platforms to develop small-molecule medicines aimed at genetically defined or otherwise difficult-to-treat tumors.

Its pipeline has included JAB-21822, also known as glecirasib, an investigational KRAS G12C inhibitor designed to target cancers driven by KRAS G12C mutations. Jacobio has also developed JAB-3312, an SHP2 inhibitor intended for use in oncology, along with other early-stage programs involving targets such as BET proteins and additional cancer-related pathways.

Jacobio conducts research and clinical-development activities primarily in China, with programs and collaborations extending to international markets, including the United States. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange; its American depositary securities trade over the counter in the United States under the symbol JBPHF.

Key Stats

• Today's Range: $0.72 to $0.72
• 50-Day Range: $0.60 to $0.74
• 52-Week Range: $0.60 to $0.74
• Volume: N/A
• Average Volume: 1,250 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:JBPHF
• CIK: N/A
• Web: www.jacobiopharma.com
• Phone: 86-10-5631-5466
• Fax: N/A
• Employees: 301
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A